{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711274",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711274_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"abemaciclib\" outputclass=\"int-drug\">abemaciclib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   abemaciclib .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Abemaciclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711275",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711275_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"acebutolol\" outputclass=\"int-drug\">acebutolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   acebutolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acebutolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711276",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711276_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"afatinib\" outputclass=\"int-drug\">afatinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 12 hours</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   afatinib .  Manufacturer advises separate administration by 12 hours .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Afatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711277",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711277_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"alfentanil\" outputclass=\"int-drug\">alfentanil</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   alfentanil .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711278",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711278_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   aliskiren .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711279",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711279_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"alprazolam\" outputclass=\"int-drug\">alprazolam</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   alprazolam .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711280",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711280_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"amifampridine\" outputclass=\"int-drug\">amifampridine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  amifampridine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amifampridine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711281",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711281_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">Aminophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aminophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aminophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711282",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711282_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  amisulpride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amisulpride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711283",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711283_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   amitriptyline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711284",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711284_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"amlodipine\" outputclass=\"int-drug\">amlodipine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   amlodipine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amlodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711285",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711285_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amphotericin\" outputclass=\"int-drug\">Amphotericin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Amphotericin   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711286",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711286_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  anagrelide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711287",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711287_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">apalutamide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  apalutamide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711288",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711288_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"apixaban\" outputclass=\"int-drug\">apixaban</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   apixaban .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711289",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711289_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  apomorphine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711290",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711290_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aprepitant\" outputclass=\"int-drug\">Aprepitant</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aprepitant   increases   the exposure to   dronedarone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aprepitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711291",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711291_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  arsenic trioxide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711292",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711292_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"artemether\" outputclass=\"int-drug\">artemether</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  artemether  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artemether</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711293",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711293_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"artenimol\" outputclass=\"int-drug\">artenimol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  artenimol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artenimol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711294",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711294_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711295",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711295_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"atenolol\" outputclass=\"int-drug\">atenolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   atenolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atenolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711296",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711296_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"atorvastatin\" outputclass=\"int-drug\">atorvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   atorvastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atorvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711297",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711297_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"avanafil\" outputclass=\"int-drug\">avanafil</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"avanafil\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/avanafil.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP104907\">avanafil</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   avanafil .  Manufacturer advises adjust  avanafil  dose .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Avanafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711298",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711298_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   axitinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711299",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711299_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bambuterol\" outputclass=\"int-drug\">Bambuterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bambuterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bambuterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711300",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711300_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">Beclometasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Beclometasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711301",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711301_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  bedaquiline  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711301_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid prolonged use</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   bedaquiline .  Manufacturer advises avoid prolonged use .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711302",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711302_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bendroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711303",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711303_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">Betamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Betamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711304",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711304_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"betaxolol\" outputclass=\"int-drug\">betaxolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   betaxolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betaxolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711305",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711305_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"bictegravir\" outputclass=\"int-drug\">bictegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   bictegravir .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bictegravir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711306",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711306_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"bisoprolol\" outputclass=\"int-drug\">bisoprolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   bisoprolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bisoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711307",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711307_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711308",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711308_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  bosutinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711308_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   bosutinib .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711309",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711309_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neutropenia when given with</ph> <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-drug\">brentuximab vedotin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   increases   the risk of neutropenia when given with   brentuximab vedotin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brentuximab vedotin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711310",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711310_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"bromocriptine\" outputclass=\"int-drug\">bromocriptine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   bromocriptine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromocriptine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711311",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711311_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"budesonide\" outputclass=\"int-drug\">Budesonide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Budesonide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711312",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711312_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">Bumetanide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bumetanide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711313",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711313_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bupivacaine\" outputclass=\"int-drug\">Bupivacaine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiodepression when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bupivacaine   is predicted to   increase   the risk of cardiodepression when given with   dronedarone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711314",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711314_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"buprenorphine\" outputclass=\"int-drug\">buprenorphine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   buprenorphine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buprenorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711315",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711315_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"buspirone\" outputclass=\"int-drug\">buspirone</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   buspirone .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buspirone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711316",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711316_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   cabazitaxel .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711317",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711317_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"cabergoline\" outputclass=\"int-drug\">cabergoline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the concentration of   cabergoline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabergoline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711318",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711318_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  cabozantinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711318_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   cabozantinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711319",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711319_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711320",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711320_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cariprazine\" outputclass=\"int-drug\">cariprazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   cariprazine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cariprazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711321",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711321_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"carvedilol\" outputclass=\"int-drug\">carvedilol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   carvedilol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carvedilol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711322",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711322_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"celiprolol\" outputclass=\"int-drug\">celiprolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   celiprolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celiprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711323",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711323_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  ceritinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711323_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ceritinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711324",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711324_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711325",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711325_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  chlorpromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711326",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711326_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chlortalidone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711327",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711327_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the concentration of   ciclosporin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711328",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711328_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  citalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711328_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   citalopram .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711329",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711329_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  clarithromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711329_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Clarithromycin   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711330",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711330_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  clomipramine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711330_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   clomipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711331",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711331_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cobicistat\" outputclass=\"int-drug\">Cobicistat</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Cobicistat   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobicistat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711332",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711332_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cobimetinib\" outputclass=\"int-drug\">cobimetinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor for toxicity</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   cobimetinib .  Manufacturer advises caution and monitor for toxicity .    \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobimetinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711333",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711333_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"colchicine\" outputclass=\"int-drug\">colchicine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"colchicine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/colchicine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP6662\">colchicine</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   colchicine .  Manufacturer advises adjust  colchicine  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Colchicine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711334",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711334_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  crizotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711335",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711335_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">dabigatran</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   slightly   increases   the exposure to   dabigatran .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/dapoxetine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34155\">dapoxetine</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   dapoxetine .  Manufacturer advises adjust  dapoxetine  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"darifenacin\" outputclass=\"int-drug\">darifenacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   slightly   increase   the exposure to   darifenacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darifenacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  dasatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711339_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   dasatinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"delamanid\" outputclass=\"int-drug\">delamanid</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  delamanid  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delamanid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">Dexamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"digoxin\" outputclass=\"int-drug\">digoxin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust <ph otherprops=\"digoxin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/digoxin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP752\">digoxin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   moderately   increase   the exposure to   digoxin .  Manufacturer advises monitor and adjust  digoxin  dose .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Digoxin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">Diltiazem</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">diltiazem</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor ECG</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Diltiazem   increases   the exposure to   dronedarone  and  dronedarone   increases   the exposure to   diltiazem .  Manufacturer advises caution and monitor ECG .    \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"domperidone\" outputclass=\"int-drug\">domperidone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   increases   the risk of QT-prolongation when given with   domperidone .  Manufacturer advises avoid .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711345_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"domperidone\" outputclass=\"int-drug\">Domperidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Domperidone   increases   the risk of QT-prolongation when given with   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Domperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   dosulepin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   doxepin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  droperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dutasteride\" outputclass=\"int-drug\">dutasteride</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   moderately   increase   the exposure to   dutasteride .  Manufacturer advises monitor side effects .    \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dutasteride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">edoxaban</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"edoxaban\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/edoxaban.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP108190\">edoxaban</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   slightly   increases   the exposure to   edoxaban .  Manufacturer advises adjust  edoxaban  dose .    \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">efavirenz</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  efavirenz  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711351_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Efavirenz   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eliglustat\" outputclass=\"int-drug\">eliglustat</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust doseconsult product literature</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   eliglustat .  Manufacturer advises avoid or adjust doseconsult product literature .    \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eliglustat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">encorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  encorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711353_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">encorafenib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   moderately   increase   the exposure to   encorafenib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"eplerenone\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/eplerenone.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP831\">eplerenone</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   eplerenone .  Manufacturer advises adjust  eplerenone  dose .    \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of ergotism when given with</ph> <ph otherprops=\"ergometrine\" outputclass=\"int-drug\">ergometrine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of ergotism when given with   ergometrine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ergometrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of ergotism when given with</ph> <ph otherprops=\"ergotamine\" outputclass=\"int-drug\">ergotamine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of ergotism when given with   ergotamine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ergotamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  eribulin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">erlotinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   erlotinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">erythromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  erythromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711360_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">Erythromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Erythromycin   is predicted to   moderately   increase   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  escitalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711361_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   escitalopram .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"esmolol\" outputclass=\"int-drug\">esmolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   esmolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esmolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"everolimus\" outputclass=\"int-drug\">everolimus</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the concentration of   everolimus .  Manufacturer advises avoid or adjust dose .    \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Everolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"felodipine\" outputclass=\"int-drug\">felodipine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   felodipine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Felodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   fentanyl .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fesoterodine\" outputclass=\"int-drug\">fesoterodine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"fesoterodine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/fesoterodine-fumarate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP5082\">fesoterodine</xref></ph> dose with moderate inhibitors of CYP3A4 in hepatic and renal impairment</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   fesoterodine .  Manufacturer advises adjust  fesoterodine  dose with moderate inhibitors of CYP3A4 in hepatic and renal impairment .    \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fesoterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fexofenadine\" outputclass=\"int-drug\">fexofenadine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   fexofenadine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fexofenadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fidaxomicin\" outputclass=\"int-drug\">fidaxomicin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   fidaxomicin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fidaxomicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fingolimod\" outputclass=\"int-drug\">Fingolimod</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fingolimod   increases   the risk of QT-prolongation when given with   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fingolimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  fluconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711370_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   dronedarone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">Fludrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fludrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   fluoxetine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"fluphenazine\" outputclass=\"int-drug\">fluphenazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  fluphenazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluphenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   fluvoxamine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"formoterol\" outputclass=\"int-drug\">Formoterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Formoterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Formoterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"furosemide\" outputclass=\"int-drug\">Furosemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Furosemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gefitinib\" outputclass=\"int-drug\">gefitinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   gefitinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gefitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glecaprevir\" outputclass=\"int-drug\">glecaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   potentially   increases   the exposure to   glecaprevir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glecaprevir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"granisetron\" outputclass=\"int-drug\">Granisetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Granisetron   is predicted to   increase   the risk of QT-prolongation when given with   dronedarone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"grapefruit juice\" outputclass=\"int-drug\">Grapefruit juice</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Grapefruit juice   moderately   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Grapefruit juice</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"guanfacine\" outputclass=\"int-drug\">guanfacine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"guanfacine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/guanfacine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP200774\">guanfacine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the concentration of   guanfacine .  Manufacturer advises adjust  guanfacine  dose .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Guanfacine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  haloperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrochlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">Hydrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  hydroxyzine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxyzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ibrutinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP101780\">ibrutinib</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ibrutinib .  Manufacturer advises adjust  ibrutinib  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"idelalisib\" outputclass=\"int-drug\">Idelalisib</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Idelalisib   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idelalisib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"imatinib\" outputclass=\"int-drug\">Imatinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Imatinib   is predicted to   increase   the exposure to   dronedarone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   imipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indacaterol\" outputclass=\"int-drug\">Indacaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indacaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indacaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indapamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  inotuzumab ozogamicin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"itraconazole\" outputclass=\"int-drug\">Itraconazole</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Itraconazole   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Itraconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivabradine\" outputclass=\"int-drug\">ivabradine</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ivabradine\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ivabradine.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1385\">ivabradine</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ivabradine .  Manufacturer advises adjust  ivabradine  dose .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711397_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivabradine\" outputclass=\"int-drug\">Ivabradine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of torsade de pointes when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Ivabradine   is predicted to   increase   the risk of torsade de pointes when given with   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ivabradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ivacaftor\" outputclass=\"int-drug\">ivacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"ivacaftor\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP33421\">ivacaftor</xref></ph> or <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ivacaftor .  Manufacturer advises adjust  ivacaftor  or  tezacaftor with ivacaftor  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ivacaftor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ketoconazole\" outputclass=\"int-drug\">Ketoconazole</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ketoconazole   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"labetalol\" outputclass=\"int-drug\">labetalol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   labetalol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Labetalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lacidipine\" outputclass=\"int-drug\">lacidipine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   lacidipine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lacidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  lapatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711402_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   lapatinib .  Manufacturer advises caution and monitor side effects .    \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  lenvatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lercanidipine\" outputclass=\"int-drug\">lercanidipine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   lercanidipine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lercanidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"levobunolol\" outputclass=\"int-drug\">levobunolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   levobunolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levobunolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"levobupivacaine\" outputclass=\"int-drug\">Levobupivacaine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiodepression when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Levobupivacaine   is predicted to   increase   the risk of cardiodepression when given with   dronedarone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levobupivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  levomepromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  lithium  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lofepramine\" outputclass=\"int-drug\">lofepramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   lofepramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofepramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  lofexidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lomitapide\" outputclass=\"int-drug\">lomitapide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   lomitapide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lomitapide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"loperamide\" outputclass=\"int-drug\">loperamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   loperamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loperamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"lopinavir\" outputclass=\"int-drug\">Lopinavir</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Lopinavir   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lopinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"lurasidone\" outputclass=\"int-drug\">lurasidone</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"lurasidone\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/lurasidone-hydrochloride.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93592\">lurasidone</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   lurasidone .  Manufacturer advises adjust  lurasidone  dose .    \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lurasidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefloquine\" outputclass=\"int-drug\">Mefloquine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefloquine   is predicted to   increase   the risk of QT-prolongation when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefloquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mepivacaine\" outputclass=\"int-drug\">Mepivacaine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiodepression when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mepivacaine   is predicted to   increase   the risk of cardiodepression when given with   dronedarone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mepivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  methadone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711417_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   methadone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">Methylprednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methylprednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711418_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">methylprednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   methylprednisolone .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Metolazone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"metoprolol\" outputclass=\"int-drug\">metoprolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   metoprolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mexiletine\" outputclass=\"int-drug\">Mexiletine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of torsade de pointes when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mexiletine   increases   the risk of torsade de pointes when given with   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mexiletine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"midazolam\" outputclass=\"int-drug\">midazolam</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor side effects and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   midazolam .  Manufacturer advises monitor side effects and adjust dose .    \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Midazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"midostaurin\" outputclass=\"int-drug\">midostaurin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   midostaurin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Midostaurin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mizolastine\" outputclass=\"int-drug\">Mizolastine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mizolastine   is predicted to   increase   the risk of QT-prolongation when given with   dronedarone .  Manufacturer advises avoid .    \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711425_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"mizolastine\" outputclass=\"int-drug\">mizolastine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   mizolastine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mizolastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  moxifloxacin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"nadolol\" outputclass=\"int-drug\">nadolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   nadolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nadolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"naloxegol\" outputclass=\"int-drug\">naloxegol</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"naloxegol\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/naloxegol.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP201107\">naloxegol</xref></ph> dose and monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   naloxegol .  Manufacturer advises adjust  naloxegol  dose and monitor side effects .    \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naloxegol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"nebivolol\" outputclass=\"int-drug\">nebivolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   nebivolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nebivolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nevirapine\" outputclass=\"int-drug\">Nevirapine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nevirapine   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nevirapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"nicardipine\" outputclass=\"int-drug\">nicardipine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   nicardipine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicardipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"nifedipine\" outputclass=\"int-drug\">nifedipine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   nifedipine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nifedipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  nilotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"nimodipine\" outputclass=\"int-drug\">nimodipine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   nimodipine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nimodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"nintedanib\" outputclass=\"int-drug\">nintedanib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   nintedanib .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nintedanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   nortriptyline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"olaparib\" outputclass=\"int-drug\">olaparib</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid moderate inhibitors of CYP3A4 or adjust <ph otherprops=\"olaparib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/olaparib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP108559\">olaparib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   olaparib .  Manufacturer advises avoid moderate inhibitors of CYP3A4 or adjust  olaparib  dose .    \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"olodaterol\" outputclass=\"int-drug\">Olodaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Olodaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olodaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  ondansetron  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">osimertinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  osimertinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"oxprenolol\" outputclass=\"int-drug\">oxprenolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   oxprenolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxprenolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxybuprocaine\" outputclass=\"int-drug\">Oxybuprocaine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiodepression when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxybuprocaine   is predicted to   increase   the risk of cardiodepression when given with   dronedarone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxybuprocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"oxybutynin\" outputclass=\"int-drug\">oxybutynin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   oxybutynin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxybutynin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"oxycodone\" outputclass=\"int-drug\">oxycodone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   oxycodone .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxycodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   paclitaxel .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  paliperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">Palonosetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Palonosetron   is predicted to   increase   the risk of QT-prolongation when given with   dronedarone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  panobinostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711448_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   panobinostat .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711449",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711449_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   paroxetine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"pasireotide\" outputclass=\"int-drug\">pasireotide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  pasireotide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pasireotide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  pazopanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711451_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   pazopanib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   pentamidine   potentially   increases   the risk of QT-prolongation when given with   dronedarone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711455",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711455_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pibrentasvir\" outputclass=\"int-drug\">pibrentasvir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   potentially   increases   the exposure to   pibrentasvir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pibrentasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711456",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711456_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  pimozide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711456_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   pimozide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711457",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711457_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"pindolol\" outputclass=\"int-drug\">pindolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   pindolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pindolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711458",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711458_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"piperaquine\" outputclass=\"int-drug\">piperaquine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor ECG</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the concentration of   piperaquine .  Manufacturer advises caution and monitor ECG .    \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piperaquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711459",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711459_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"posaconazole\" outputclass=\"int-drug\">Posaconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Posaconazole   is predicted to   increase   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Posaconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711460",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711460_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">Prednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711461",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711461_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prilocaine\" outputclass=\"int-drug\">Prilocaine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiodepression when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prilocaine   is predicted to   increase   the risk of cardiodepression when given with   dronedarone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prilocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711462",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711462_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711463",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711463_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"propafenone\" outputclass=\"int-drug\">propafenone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   propafenone .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propafenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711464",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711464_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"propranolol\" outputclass=\"int-drug\">propranolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   propranolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propranolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711465",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711465_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"proxymetacaine\" outputclass=\"int-drug\">Proxymetacaine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiodepression when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Proxymetacaine   is predicted to   increase   the risk of cardiodepression when given with   dronedarone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Proxymetacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711466",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711466_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">quetiapine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   quetiapine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quetiapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711467",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711467_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"quinine\" outputclass=\"int-drug\">quinine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  quinine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711468",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711468_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"ranolazine\" outputclass=\"int-drug\">ranolazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  ranolazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711468_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ranolazine\" outputclass=\"int-drug\">ranolazine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ranolazine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranolazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711469",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711469_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  ribociclib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711469_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ribociclib .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711470",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711470_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711471",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711471_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  risperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711472",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711472_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ritonavir\" outputclass=\"int-drug\">Ritonavir</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ritonavir   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ritonavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711473",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711473_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">rivaroxaban</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   rivaroxaban .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711474",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711474_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ropivacaine\" outputclass=\"int-drug\">Ropivacaine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiodepression when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ropivacaine   is predicted to   increase   the risk of cardiodepression when given with   dronedarone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711475",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711475_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   slightly   increases   the exposure to   rosuvastatin .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rosuvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711476",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711476_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rupatadine\" outputclass=\"int-drug\">rupatadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   rupatadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rupatadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711477",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711477_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor side effects</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ruxolitinib .  Manufacturer advises monitor side effects .    \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711478",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711478_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salbutamol\" outputclass=\"int-drug\">Salbutamol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salbutamol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salbutamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711479",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711479_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salmeterol\" outputclass=\"int-drug\">Salmeterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salmeterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salmeterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711480",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711480_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">saquinavir</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  saquinavir  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711480_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"saquinavir\" outputclass=\"int-drug\">Saquinavir</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Saquinavir   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saquinavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711481",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711481_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"saxagliptin\" outputclass=\"int-drug\">saxagliptin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   saxagliptin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saxagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711482",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711482_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   sertraline .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711483",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711483_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  sildenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711483_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor or adjust <ph otherprops=\"sildenafil\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/sildenafil.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1059\">sildenafil</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   sildenafil .  Manufacturer advises monitor or adjust  sildenafil  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711484",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711484_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"simvastatin\" outputclass=\"int-drug\">simvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust <ph otherprops=\"simvastatin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/simvastatin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP1647\">simvastatin</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   simvastatin .  Manufacturer advises use with caution and adjust  simvastatin  dose .    \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Simvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711485",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711485_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"sirolimus\" outputclass=\"int-drug\">sirolimus</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   increases   the concentration of   sirolimus .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711486",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711486_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  sorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711487",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711487_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  sotalol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711487_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   sotalol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711488",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711488_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's Wort\" outputclass=\"int-drug\">St John's Wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "St John's Wort   is predicted to   decrease   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's Wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711489",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711489_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"sufentanil\" outputclass=\"int-drug\">sufentanil</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   sufentanil .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sufentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711490",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711490_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  sulpiride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711491",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711491_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  sunitinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711491_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   sunitinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711492",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711492_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the concentration of   tacrolimus .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711493",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711493_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tadalafil\" outputclass=\"int-drug\">tadalafil</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   tadalafil .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tadalafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711494",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711494_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tamsulosin\" outputclass=\"int-drug\">tamsulosin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   tamsulosin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tamsulosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711495",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711495_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"telavancin\" outputclass=\"int-drug\">telavancin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  telavancin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telavancin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711496",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711496_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"temsirolimus\" outputclass=\"int-drug\">temsirolimus</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the concentration of   temsirolimus .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temsirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711497",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711497_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"terbutaline\" outputclass=\"int-drug\">Terbutaline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Terbutaline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbutaline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711498",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711498_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"tetrabenazine\" outputclass=\"int-drug\">tetrabenazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  tetrabenazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetrabenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711499",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711499_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tetracaine\" outputclass=\"int-drug\">Tetracaine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiodepression when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tetracaine   is predicted to   increase   the risk of cardiodepression when given with   dronedarone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetracaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711500",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711500_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tezacaftor\" outputclass=\"int-drug\">tezacaftor</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <xref format=\"dita\" href=\"drug/tezacaftor-with-ivacaftor.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP218356\">tezacaftor with ivacaftor</xref> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   tezacaftor .  Manufacturer advises adjust  tezacaftor with ivacaftor  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tezacaftor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711501",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711501_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"theophylline\" outputclass=\"int-drug\">Theophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Theophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Theophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of cardiovascular side-effects when given with</ph> <ph otherprops=\"timolol\" outputclass=\"int-drug\">timolol</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the risk of cardiovascular side-effects when given with   timolol .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Timolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "230",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  tizanidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "231",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-substanceQualifier\">given with a potent CYP2C19 inhibitor</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tofacitinib\" outputclass=\"int-drug\">tofacitinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"tofacitinib\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/tofacitinib.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP213798\">tofacitinib</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   given with a potent CYP2C19 inhibitor   is predicted to   increase   the exposure to   tofacitinib .  Manufacturer advises adjust  tofacitinib  dose .    \n\n"
						}
					],
					"hasOrder": "232",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tofacitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  tolterodine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711506_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Mild",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   tolterodine .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "233",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution or adjust <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/tolvaptan.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP4640\">tolvaptan</xref></ph> dose with moderate inhibitors of CYP3A4</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   tolvaptan .  Manufacturer advises caution or adjust  tolvaptan  dose with moderate inhibitors of CYP3A4 .    \n\n"
						}
					],
					"hasOrder": "234",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   topotecan .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "235",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"torasemide\" outputclass=\"int-drug\">Torasemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Torasemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "236",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  toremifene  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "237",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"trametinib\" outputclass=\"int-drug\">trametinib</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the concentration of   trametinib .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "238",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trametinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   trazodone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "239",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">Triamcinolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Triamcinolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "240",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   trimipramine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "241",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ulipristal\" outputclass=\"int-drug\">ulipristal</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid if used for uterine fibroids</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   ulipristal .  Manufacturer advises avoid if used for uterine fibroids .    \n\n"
						}
					],
					"hasOrder": "242",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ulipristal</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"vandetanib\" outputclass=\"int-drug\">vandetanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  vandetanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "243",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vandetanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  vardenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711517_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   vardenafil .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "244",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"vemurafenib\" outputclass=\"int-drug\">vemurafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  vemurafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "245",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vemurafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"venetoclax\" outputclass=\"int-drug\">venetoclax</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust doseconsult product literature</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   venetoclax .  Manufacturer advises avoid or adjust doseconsult product literature .    \n\n"
						}
					],
					"hasOrder": "246",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venetoclax</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  venlafaxine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "247",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"verapamil\" outputclass=\"int-drug\">Verapamil</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"verapamil\" outputclass=\"int-drug\">verapamil</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor ECG</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Verapamil   increases   the exposure to   dronedarone  and  dronedarone   increases   the exposure to   verapamil .  Manufacturer advises caution and monitor ECG .    \n\n"
						}
					],
					"hasOrder": "248",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"vilanterol\" outputclass=\"int-drug\">Vilanterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Vilanterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "249",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vilanterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   vinblastine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "250",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   vincristine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "251",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   vindesine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "252",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  vinflunine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711526_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   vinflunine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "253",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   vinorelbine .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "254",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  voriconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711528_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-magnitude\">very markedly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Voriconazole   very markedly   increases   the exposure to   dronedarone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "255",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Xipamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   dronedarone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "256",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">Dronedarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"zopiclone\" outputclass=\"int-drug\">zopiclone</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dronedarone   is predicted to   increase   the exposure to   zopiclone .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "257",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zopiclone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2#bnf_i1557280711531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"dronedarone\" outputclass=\"int-heading-drug\">dronedarone</ph> and <ph otherprops=\"zuclopenthixol\" outputclass=\"int-drug\">zuclopenthixol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  dronedarone  and  zuclopenthixol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "258",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zuclopenthixol</title>"
					}
				}
			],
			"hasSearchLabel": " Dronedarone  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/dronedarone-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Dronedarone </title>"
			},
			"rdfs:label": "dronedarone"
		}
	]
}